

# Risk stratification in cardiomyopathy

Gianfranco Sinagra<sup>1</sup>, Cosimo Carriere<sup>1</sup>, Francesco Clemenza<sup>2</sup>, Chiara Minà<sup>2</sup>, Francesco Bandera<sup>3</sup>, Denise Zaffalon<sup>1</sup>, Paola Gugliandolo<sup>3</sup>, Marco Merlo<sup>1</sup>, Marco Guazzi<sup>3</sup> and Piergiuseppe Agostoni<sup>3,4</sup>

European Journal of Preventive  
Cardiology  
2020, Vol. 27(2S) 52–58  
© The European Society of  
Cardiology 2020



Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/2047487320961898  
journals.sagepub.com/home/cpr



## Abstract

Prognostic stratification of cardiomyopathies represents a cornerstone for the appropriate management of patients and is focused mainly on arrhythmic events and heart failure. Cardiopulmonary exercise testing provides additional prognostic information, particularly in the setting of heart failure. Cardiopulmonary exercise testing data, integrated in scores such as the Metabolism Exercise Cardiac Kidney Index score have been shown to improve the risk stratification of these patients. Cardiopulmonary exercise testing has been analysed as a potential supplier of prognostic parameters in the context of hypertrophic cardiomyopathy, for which it has been shown that a reduced oxygen consumption peak, an increased ventilation/carbon dioxide production slope and chronotropic incompetence correlate with a worse prognosis. To a lesser extent, in dilated cardiomyopathy, it has been shown that the percentage of oxygen consumption peak, not the pure value, and the ventilation/carbon dioxide production slope are associated with a greater cardiovascular risk. Few data are available about other cardiomyopathies (arrhythmogenic and restrictive). Cardiomyopathy patients should be early and routinely referred to heart failure advanced centres in order to perform a comprehensive risk stratification which should include a cardiopulmonary exercise test, with variables and cut-offs shown to improve their risk stratification.

## Keywords

Cardiomyopathy, CPET, risk stratification, prognosis, exercise, MECKY score

Received 17 August 2020; accepted 2 September 2020

## Introduction

Cardiomyopathies represent a heterogeneous group of heart muscle disorders in the absence of conditions such as coronary heart disease, hypertension or valvular disease.<sup>1</sup> Cardiomyopathies may be primary or secondary, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM) and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). Prognostic stratification is a cornerstone and a component of paramount importance for appropriate management in these patients, and it is focused mainly on arrhythmic events and heart failure (HF).<sup>2</sup> Recent progress in early diagnosis, biomarker interpretation, comprehensive characterisation and tailored follow-up has allowed a better prognostic stratification of cardiomyopathies.<sup>2,3</sup> Despite significant improvements in this field during the past two decades, research is still

focused on improving. In this context, cardiopulmonary exercise testing (CPET) represents a valuable tool providing additional prognostic information, particularly in the setting of HF. In all stages and types of HF, from reduced to preserved ejection fraction, CPET data have been demonstrated as useful tools, when

<sup>1</sup>Cardiothoracovascular Department of Trieste, University of Trieste, Italy

<sup>2</sup>Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Italy

<sup>3</sup>Centro Cardiologico Monzino, IRCCS, Italy

<sup>4</sup>Department of Clinical Sciences and Community Medicine, University of Milan, Italy

## Corresponding author:

Cosimo Carriere, Cardiothoracovascular Department of Trieste and University of Trieste, Via Pietro Valdoni 7, 34149 Trieste (TS), Italy.  
Email: cosimocarriere83@gmail.com


added in scores that include clinical, laboratory and other instrumental variables, such as the metabolism exercise cardiac kidney index (MECKI) score (Figure 1).<sup>4,5</sup> At the same time, CPET variables are influenced by several factors: among others, recent data suggest for example that obesity may negatively affect peak oxygen consumption ( $\text{VO}_2$ ).<sup>6</sup> Therefore, the assumption that their prognostic ability is reproducible to all patients with HF of its aetiology can be misleading in clinical practice. Consequently, CPET data need to be contextualised into specific groups of cardiomyopathies. The main studies analysed are summarised in Table 1.

### Dilated cardiomyopathy

DCM is a primary heart muscle disease characterised by progressive left ventricular or biventricular dilation and dysfunction in the absence of conditions such as hypertension, ischaemic and valvular disease. DCM represents one of the main causes of heart transplantation (HTx) and is associated with an increased risk of arrhythmia-related death.<sup>2</sup> Risk stratification in these patients continues to be challenging and the natural history still remains characterised by a progressive incidence of HF, with significant morbidity and mortality. An accurate clinical assessment of patients with DCM

is crucial to identify those who are more likely to die from sudden death or for progressive HF.

Until now, peak  $\text{VO}_2$  has been used as a pivotal criterion for selecting DCM patients for HTx. Nevertheless, DCM patients represent a peculiar model compared to heart failure with reduced ejection fraction (HFrEF) patients with other aetiologies. They are mostly young, with a lower comorbidity profile and are usually less symptomatic at disease onset. This explains better cardiopulmonary performances at early stages of the disease and a lower risk of events compared to other HFrEF aetiologies. Also, in patients with a long duration of asymptomatic left ventricular dysfunction, adaptive pathophysiological cardiopulmonary mechanisms can lead to better performances on CPET, with a better prognostic impact compared to patients with similar left ventricular dysfunction of different aetiologies (i.e. ischaemic).<sup>7</sup> Although CPET is recognised as an important tool in risk stratification of HF patients, prognostic data in the specific setting of DCM have not been available until a few years ago. The first pioneering study dates back to 2016, led by the cardiology department of Centro Cardiologico Monzino and Trieste Hospital in a large cohort of 'pure' DCM patients who consecutively performed CPET. The study findings showed that peak  $\text{VO}_2\%$  (the percentage of  $\text{VO}_2$  obtained compared to the



**Figure 1.** Parameters for the calculation of the metabolism exercise cardiac kidney index (MECKI) score: metabolic exercise (peak  $\text{VO}_2\%$  pred,  $\text{VE}/\text{VCO}_2$  slope), cardiac (LVEF), kidney (MDRD, ml/min), index.

$\text{VO}_2$ : oxygen consumption; LVEF: left ventricular ejection fraction; MDRD: Modification of Diet in Renal Disease study. VE: ventilation;  $\text{VCO}_2$ : carbon dioxide production.

**Table 1.** Results and main findings of leading studies about CPET in CMPs.


CMP	Authors	Numbers	Results and CPET prognostic values
DCM	Sinagra, Agostoni et al. <sup>8</sup>	381	Peak VO <sub>2</sub> /kg was not independently related with prognosis VO <sub>2</sub> <60% and VE/VCO <sub>2</sub> slope >29 were independently correlated with VD or HTx
	Hirashiki et al. <sup>10</sup>	90	Lower % peak VO <sub>2</sub> , greater VE/VCO <sub>2</sub> slope, and lower VO <sub>2</sub> /work correlated with PH A peak VO <sub>2</sub> <52% of predicted was associated with a mPAP of >25 mmHg
HCM	Masri et al. <sup>26</sup>	1005	Peak VO <sub>2</sub> <50 % of predicted was independently associated with overall mortality and SCD
	Magri et al. <sup>14</sup>	620	'Circulatory power' (predicted peak VO <sub>2</sub> % * peak SBP), VE/VCO <sub>2</sub> slope and left atrial predicted HF-related death, hospitalisation and worsening of symptoms Mean peak VO <sub>2</sub> = 21 ml/kg/min (71%) Mean VE/VCO <sub>2</sub> slope = 29
	Magri et al. <sup>27</sup>	623	VE/VCO <sub>2</sub> slope >31 was the only CPET variable to be independently associated with SCD
	Finocchiaro et al. <sup>28</sup>	156	Peak exercise cardiac output is the primary determinant in exercise tolerance: a peak VO <sub>2</sub> <20 ml/kg/min or <80% of predicted was associated with worse prognosis; indices of ventilatory inefficiency are only weakly associated with diastolic parameters A VE/VCO <sub>2</sub> slope >34 and left atrial dimension emerged as main predictors of overall mortality, HTx, deterioration to septal reduction
	Coats et al. <sup>29</sup>	1898	Independent relationship between peak VO <sub>2</sub> and VE/VCO <sub>2</sub> slope and death from HF: the reduction of 21% in the risk of death/HTx for each 1 ml/kg/min increase in peak VO <sub>2</sub> and by 29% for each 1 ml/kg/min increase in AT. The risk of death/HTx is increased by 18% for each unit increase in VE/VCO <sub>2</sub> slope
ARVC/D	Magri et al. <sup>30</sup>	81	pHR (peak HR) < 70% was correlated with HF-related events
	Magri et al. <sup>15</sup>	681	Peak HR was a prognostic factor for HF-related events and SCD
	Scheel et al. <sup>24</sup>	38	Safety and prognostic capability of CPET Maximal exercise effort had not achieved in about a quarter of them VE/VCO <sub>2</sub> slope was the main prognostic predictor
RCM	Sayegh et al. <sup>19</sup>	26	Normal VE/VCO <sub>2</sub> slope Reduced peak workload, VO <sub>2</sub> , O <sub>2</sub> pulse, VCO <sub>2</sub> , VE
	Sayegh et al. <sup>20</sup>	15	Peak VO <sub>2</sub> similar between RCM and DCM, both less than HS

ARVC/D: arrhythmogenic right ventricle cardiomyopathy/dysplasia; AT: anaerobic threshold; CMPs: cardiomyopathies; CPET: cardiopulmonary exercise testing; CVD: cardiovascular disease; DCM: dilated cardiomyopathy; HS: healthy subjects; HTx: heart transplantation; mPAP: mean pulmonary artery pressure; HCM: hypertrophic cardiomyopathy; HF: heart failure; HR: heart rate; PH: pulmonary hypertension; SBP: systolic blood pressure; SCD: sudden cardiac death; VO<sub>2</sub>: oxygen uptake; VE: ventilation; VCO<sub>2</sub>: carbon dioxide consumption; VE/VCO<sub>2</sub>: ventilation/carbon dioxide consumption.

theoretical VO<sub>2max</sub> of a normal subject of the same age, weight, sex and ethnicity) and the ventilation/carbon dioxide production (VE/VCO<sub>2</sub>) slope were the strongest predictors of cardiovascular death/urgent HTx. Interestingly, peak VO<sub>2</sub>/kg was not independently related to prognosis (Figure 2). This finding highlights how in DCM the absolute value of VO<sub>2</sub>/kg peak does not precisely represent the true impairment of cardiovascular fitness of DCM patients. A predicted VO<sub>2</sub> less than 60% and a VE/VCO<sub>2</sub> slope greater than 29 were associated with poor prognosis in the study population. In this cohort of 'pure' DCM patients, these cut-points were slightly different and more accurate than those

previously described in CPET among HFrEF patients in prognostic stratification. In view of the above, the importance of an aetiological classification upstream of HF was emphasised to differentiate specific cut-points for the identification of high-risk patients.<sup>8</sup> Among the cardiomyopathies, DCM is probably the one that best fits in the characterisation given by the MECKI score as it has been validated on HFrEF patients.

In recent years there has also been growing emphasis on the role of pulmonary hypertension (PH) in the prognosis of HF patients with DCM.<sup>9</sup> In this setting, PH secondary to left ventricular dysfunction is frequent and is a consolidated predictor of mortality



**Figure 2.** Survival free from cardiovascular death/heart transplantation in dilated cardiomyopathy (DCM) patients. Kaplan–Meier survival curves stratified by peak  $\text{VO}_2/\text{kg}$  (14–12 mL/kg/min refers to the classically used cut-points for peak  $\text{VO}_2$ , respectively, in the presence or absence of beta-blocker therapy, upper left panel), peak  $\text{VO}_2\%$  cut-point 60%, upper right panel),  $\text{VE}/\text{VCO}_2$  slope (cut-point 29, bottom left panel), combination of peak  $\text{VO}_2\%$  (cut-point 60%) and  $\text{VE}/\text{VCO}_2$  slope (cut-point 29, bottom right panel). D/HTx: cardiovascular death/heart transplantation; peak  $\text{VO}_2/\text{kg}$ : peak of oxygen consumption per kg; peak  $\text{VO}_2\%$ : percentage of predicted oxygen consumption;  $\text{VCO}_2$ : carbon dioxide production; VE: ventilation. Reproduced from Sinagra et al.,<sup>8</sup> with permission.

and morbidity. In a work by Hirashiki et al. %peak  $\text{VO}_2$  was the best predictor of PH in DCM patients and a reduction below 52% was strongly related to the presence of mean pulmonary arterial pressure (mPAP) greater than 25 mmHg. Likewise,  $\text{VO}_2$  peak,  $\text{VE}/\text{VCO}_2$  slope and  $\text{VO}_2/\text{work}$  were other variables related to the presence of PH in DCM patients.<sup>10</sup> Within the DCM spectrum there are also different pathophysiological mechanisms; in a few cases several factors such as excessive alcohol consumption,<sup>11</sup> arrhythmias<sup>12</sup> or drugs (e.g. anthracycline) can unmask the DCM phenotype. Further studies will be needed to understand if these cardiomyopathies can express themselves differently in CPET.

Finally, DCM behaves as a dynamic disease with a need for continuous re-stratification of risk during follow-up: to date, there is no clear consensus on how often is reasonable to repeat a CPET in order to monitor its changes during DCM patients' follow-up. It seems reasonable to propose to repeat it every 1–2 years.

## Hypertrophic cardiomyopathy

HCM is an inherited genetic disease characterised by left ventricular hypertrophy unexplained by abnormal loading conditions<sup>13</sup> and represents the most common cardiomyopathy occurring in nearly 1:500 of the general population. Sudden cardiac death (SCD), albeit rare (0.5–1% per year), is a catastrophic event, caused by fatal arrhythmias in generally young men (between the third and fourth decade of life). Currently, in a subset of HCM patients, SCD is still an unpredictable complication and may represent the first manifestation of the disease. In light of this, the assessment of arrhythmic risk is a cornerstone of management in HCM patients. However, recent studies point to the growing role of HF and stroke-related death as important causes of morbidity and mortality in the long term. Recently, the European Society of Cardiology (ESC) guidelines included in the indications for the execution of CPET also the evaluation of the severity and causes for exercise intolerance, the

assessment of systolic blood pressure changes during exercise and the early identification of candidates for septal reduction procedures.<sup>14</sup>


In these patients, exercise limitation is primarily due to the inability to increase stroke volume secondary to left ventricular diastolic dysfunction, chronotropic incompetence and left ventricular outflow obstruction.<sup>15–17</sup> For these pathophysiological features of HCM, the oxygen pulse curve (a derived CPET parameter reflecting stroke volume) may display an early flattening due to an inability of the left ventricle to increase the stroke volume, as shown in Figure 3.<sup>14</sup> This finding, in those subjects without chronotropic incompetence, is associated with a compensatory heart rate increase, and its earliness correlates with the prognosis.<sup>15</sup> Furthermore, an increase of pulmonary pressures, the worsening of mitral regurgitation and the impaired peripheral oxygen uptake due to a low mitochondrial density in skeletal muscle can contribute to a reduction in exercise capability. In haemodynamically stable patients the  $\text{VO}_2/\text{work}$  slope, a marker of aerobic work efficiency, is usually preserved. An important pathophysiological feature in these patients is exercise-induced myocardial ischaemia, which can be highlighted during CPET by a sudden flattening of the  $\text{VO}_2/\text{work}$  slope, in which the analysis of repolarisation on ECG can often be inconclusive. From a prognostic point of view, several studies have been conducted. They are summarised in detail in Table 1. In HCM patients, a reduced  $\text{VO}_2$  peak (i.e.  $<50\%$ ) and high  $\text{VE}/\text{VCO}_2$  slope are associated with overall mortality and SCD. Moreover, chronotropic incompetence emerged as an important prognostic factor for HF-related events.<sup>15</sup>

## Restrictive cardiomyopathy

RCM is a myocardial disease characterised by an increase of myocardial stiffness that leads to impaired ventricular filling.<sup>18</sup> Many aetiologies can lead to an RCM phenotype, such as infiltrative disorders (amyloidosis, Gaucher disease, Hurler syndrome, fatty or glycogen infiltration, Fabry disease, haemochromatosis).<sup>18</sup> Hypertrophy is not typical, although in the case of some infiltrative diseases (e.g. cardiac amyloidosis) and storage diseases (e.g. Fabry disease) an increased left ventricular thickness might be present. Systolic function is usually preserved, although it can be reduced in advanced stages of the disease. To our knowledge, investigations focused on the role of CPET in RCM are lacking.

Sayegh et al.<sup>19</sup> conducted CPET on 26 patients with endomyocardial fibrosis: they were mostly women, with pure diastolic dysfunction. The authors demonstrated a normal  $\text{VE}/\text{VCO}_2$  slope and respiratory exchange ratio achievement. On the other hand, reduced stroke volume parameters (peak workload,  $\text{VO}_2$ , oxygen ( $\text{O}_2$ ) pulse,  $\text{VCO}_2$  and  $\text{VE}$ ) have been described. Given that the left ventricular ejection fraction (LVEF) in these patients was preserved, the reason for these findings is presumably to be attributed to poor peripheral perfusion.

The same authors also compared CPETs of 15 patients with RCM, 10 patients with DCM and 10 healthy subjects finding that peak  $\text{VO}_2$  was similar between both cardiomyopathies but lower compared with healthy subjects, showing the same reduction in functional capacity between RCM and DCM.<sup>20</sup> In the broader setting of HF and preserved ejection fraction, both peak  $\text{VO}_2$  and the  $\text{VE}/\text{VCO}_2$  slope are able to



**Figure 3.** Relationships between oxygen pulse ( $\text{VO}_2/\text{HR}$ ) versus heart rate (HR) in a patient with asymptomatic hypertrophic cardiomyopathy (HCM) (left column) and in a patient with New York Heart Association (NYHA II) mildly symptomatic HCM with end-stage phase (right column). Although different in magnitude, both patients showed a reduced  $\text{VO}_2$  peak (70% and 55%), an early oxygen pulse flattening with a compensatory HR increase. Reproduced from Magri and Santolamazza,<sup>14</sup> with permission.

provide incremental prognostic information regarding all-cause mortality and for incident HF hospitalisation, beyond relevant classical clinical covariates.<sup>21</sup> These findings support the notion that CPET is a robust albeit underutilised tool for risk stratification in heart failure with preserved ejection fraction (HFpEF) as well.

Accordingly, the low sample size of these studies does not allow us to generalise these results widely.

### Arrhythmogenic right ventricular cardiomyopathy/dysplasia

ARVC/D is a rare genetic cardiomyopathy (incidence from 1:2000 to 1:5000) characterised by fibrofatty replacement of cardiomyocytes, resulting in right ventricular dysfunction and life-threatening ventricular arrhythmias. Despite the poor incidence, the typical ARVC/D onset is between the third and fifth decade of life, not rarely with SCD, which remains a fearsome presentation.<sup>22</sup> According to recent studies, there is a phenotypic overlap between involvement of the right ventricle, the left ventricle and DCM.<sup>23</sup> Further studies are needed to outline its characteristics and their relationship with CPET. Nevertheless, in recent years an early diagnosis and intervention (e.g. with implants of cardiac implantable defibrillators) have improved the life expectancy of ARVC/D patients. Consequently, other progressive manifestations such as right and left-sided HF became important features in the natural history of the disease. Robust data on the role of CPET for prognostic stratification in ARVC/D are still lacking. In the first and recent study, Scheel et al.<sup>24</sup> demonstrated both the safety and prognostic capability of CPET in a large ARVC/D cohort, although the maximal exercise effort was not achieved in about a quarter of the patients who performed a submaximal test (i.e. maximal beta-blocker therapy, fear of developing arrhythmias by effort). In this cohort the VE/VCO<sub>2</sub> slope proved to be the main prognostic predictor of transplant-free survival, confirming the close relationship between impaired right ventricular function, VE/VCO<sub>2</sub> and symptomatic HF.<sup>25</sup> Despite these promising data encouraging the use of CPET in ARVC/D patients, further studies will be needed to clarify the prognostic role of CPET in these cohorts of patients.

### Conclusions

Currently, the risk stratification in cardiomyopathies is a very actual issue. CPET represents an important prognostic tool to stratify both the arrhythmic risk and HF-related events. CPET-derived variables and existing cut-offs showed their best prognostic ability when tailored according to the specific

cardiomyopathies, suggesting a more personalised approach. Cardiomyopathy patients should be early and routinely referred to HF advanced centres in order to perform a comprehensive risk stratification which should include a CPET.

### Acknowledgements

This paper is dedicated to the memory of Professor Fulvio Camerini, foremost expert in cardiomyopathies, outstanding clinician and scientist. The author(s) would like to thank Fondazione CR Trieste, and FINCANTIERI for their support. They are also grateful to all the healthcare professionals for the continuous support to the research and clinical management of patients and families with cardiomyopathies followed in the HF outpatient clinic and cardiomyopathy centre of Trieste.

### Author contribution

All author(s) contributed to the conception or design of the work. All authors contributed to the acquisition, analysis, or interpretation of data for the work. All authors drafted and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work ensuring integrity and accuracy.

### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### References

1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. *Eur Heart J* 2008; 29: 270–276.
2. Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019; 21: 553–576.
3. Arzilli C, Aimo A, Vergaro G, et al. N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. *Eur J Prev Cardiol* 2018; 25: 889–895. DOI: 10.1177/2047487318766580.
4. Corrà U, Agostoni P, Giordano A, et al. The metabolic exercise test data combined with Cardiac and Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. *Int J Cardiol* 2016; 203: 1067–1072.
5. Guazzi M. Cardiopulmonary exercise testing and risk stratification in heart failure with reduced, midrange or preserved ejection fraction: when nomenclature may not

- match with pathophysiology. *Eur J Prev Cardiol* 2018; 25: 392–394. DOI: 10.1177/2047487317748456.
6. Van Iterson EH, Kim CH, Uithoven K, et al. Obesity and hemoglobin content impact peak oxygen uptake in human heart failure. *Eur J Prev Cardiol* 2018; 25: 1937–1946.
  7. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. *J Am Coll Cardiol* 1996; 27: 345–352.
  8. Sinagra G, Iorio A, Merlo M, et al. Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. *Int J Cardiol* 2016; 223: 596–603.
  9. Sinagra G, Merlo M, Pinamonti B (eds). *Dilated Cardiomyopathy: From Genetics to Clinical Management*. Springer 2019, pp. 187–198.
  10. Hirashiki A, Kondo T, Okumura T, et al. Cardiopulmonary exercise testing as a tool for diagnosing pulmonary hypertension in patients with dilated cardiomyopathy. *Ann Noninvasive Electrocardiol* 2016; 21: 263–271.
  11. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic etiology for alcohol-induced cardiac toxicity. *J Am Coll Cardiol* 2018; 71: 2293–2302.
  12. Huizar JF, Ellenbogen KA, Tan AY, et al. Arrhythmia-induced cardiomyopathy. *J Am Coll Cardiol* 2019; 73: 2328–2344.
  13. Zamorano JL, Anastakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 2014; 35: 2733–2779.
  14. Magri D and Santolamazza C. Cardiopulmonary exercise test in hypertrophic cardiomyopathy. *Ann Am Thorac Soc* 2017; 14: S102–S109.
  15. Magri D, Agostoni P, Sinagra G, et al. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. *Int J Cardiol* 2018; 271: 125–131.
  16. Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. *Am J Cardiol* 2000; 86: 162–168.
  17. Jones S, Elliott PM, Sharma S, et al. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. *Heart* 1998; 80: 60–67.
  18. Muchtar E, Blauwet LA and Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circ Res* 2017; 121: 819–837.
  19. Sayegh ALC, dos Santos MR, de Oliveira P, et al. Characterization of cardiopulmonary exercise testing variables in patients with endomyocardial fibrosis after endocardial resection. *Arq Bras Cardiol* 2017; 109: 533–540.
  20. Sayegh ALC, dos Santos MR, Sarmiento AO, et al. Cardiac and peripheral autonomic control in restrictive cardiomyopathy. *ESC Heart Fail* 2017; 4: 341–350.
  21. Reddy YNV, Olson TP, Obokata M, et al. Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. *JACC Heart Fail* 2018; 6: 665–675.
  22. Pinamonti B. Arrhythmogenic right ventricular cardiomyopathy: from genetics to diagnostic and therapeutic challenges. *World J Cardiol* 2014; 6: 1234.
  23. Corrado D, Basso C, and Judge DP. Arrhythmogenic cardiomyopathy. *Circ Res* 2017; 121: 785–802.
  24. Scheel PJ, Florido R, Hsu S, et al. Safety and utility of cardiopulmonary exercise testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *J Am Heart Assoc* 2020; 9: e013695.
  25. Guazzi M, Villani S, Generati G, et al. Right ventricular contractile reserve and pulmonary circulation uncoupling during exercise challenge in heart failure: pathophysiology and clinical phenotypes. *JACC Heart Fail* 2016; 4: 625–635.
  26. Masri A, Pierson L, Smedira NG, et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. *Am Heart J* 2015; 169: 684–692.
  27. Magri D, Limongelli G, Re F, et al. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. *Heart* 2016; 102: 602–609.
  28. Finocchiaro G, Haddad F, Knowles JW, et al. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. *J Am Coll Cardiol Heart Fail* 2015; 3: 408–418.
  29. Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. *Circ Heart Fail* 2015; 8: 1022–1031.
  30. Magri D, Agostoni P, Sinagra G, et al. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. *Int J Cardiol* 2018; 271: 125–131.